Christopher Rold

Christopher Rold has a diverse work experience spanning multiple industries and roles. Christopher is currently employed at Adicet Bio, Inc as the Vice President of Vector Development and QC, where they started in February 2022. Prior to this, they worked at Adicet Bio, Inc as the Senior Director and Head of Viral Vector Operations from July 2020 to January 2022.

Before joining Adicet Bio, Inc, Christopher was a Principal Scientist in Vector Process Development at TCR² Therapeutics Inc. from March 2018 to July 2020. Christopher also worked as a Private Biotechnology Consultant from July 2016 to March 2018.

Their earlier experience includes roles such as Director of Operations at ImmunoScience, Inc. from July 2011 to October 2016, and a Postdoctoral Fellow at Northwestern University Medical Center from May 2009 to April 2011.

Christopher's career started as a Research Technician at Visible Genetics Inc. (now Bayer Inc) from January 2000 to June 2002, where they were part of the research team involved in designing and testing the TRUGENE HIV-1 Genotyping Kit. Christopher was also responsible for testing and analyzing samples from clinical trials and producing Viral Certification Panels.

Prior to that, they worked as a Research Technician at Johns Hopkins Medical Center from January 1996 to January 1997, where their responsibilities included maintaining drosophila stockpiles and genetic selection and isolation of mutant phenotype drosophila.

Christopher Rold completed their Bachelor of Arts degree in Biology at The Johns Hopkins University, from 1994 to 1998. Following this, they pursued their Doctorate degree in Microbiology and Immunology from Vanderbilt University's Department of Microbiology and Immunology, attending from 2002 to 2009.